Matches in Wikidata for { <http://www.wikidata.org/entity/Q91455803> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q91455803 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91455803 description "scientific article published on 26 November 2019" @default.
- Q91455803 description "wetenschappelijk artikel" @default.
- Q91455803 description "наукова стаття, опублікована 26 листопада 2019" @default.
- Q91455803 name "Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer" @default.
- Q91455803 name "Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer" @default.
- Q91455803 type Item @default.
- Q91455803 label "Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer" @default.
- Q91455803 label "Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer" @default.
- Q91455803 prefLabel "Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer" @default.
- Q91455803 prefLabel "Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer" @default.
- Q91455803 P1433 Q91455803-350EE6A3-2D74-4801-8C8C-41400EAFBD09 @default.
- Q91455803 P1476 Q91455803-B19454C5-B779-4CD6-AD14-72230864E395 @default.
- Q91455803 P2093 Q91455803-267ECEB0-A05E-40B2-A6D3-87D67466F8D0 @default.
- Q91455803 P2093 Q91455803-26F462B5-F027-4031-B33D-851B5FEFF947 @default.
- Q91455803 P2093 Q91455803-AB3A897D-5DA6-450C-99EE-9E4FA665BCC0 @default.
- Q91455803 P304 Q91455803-36D0F7F3-4254-4485-9913-214BD1D2AA74 @default.
- Q91455803 P31 Q91455803-F58B0D8E-A0E1-414B-ABAF-50E993013322 @default.
- Q91455803 P356 Q91455803-36450403-0D2B-403B-ABCB-D8CA4419DBBF @default.
- Q91455803 P433 Q91455803-90BCB625-62A7-4B0A-8D67-398DD47B7DE5 @default.
- Q91455803 P4510 Q91455803-6C7C2FB7-9298-49C6-B9F4-DB26F34DB066 @default.
- Q91455803 P478 Q91455803-2B48D05C-009D-43B3-AC0A-502642751687 @default.
- Q91455803 P577 Q91455803-2CD545FD-A8D2-4D1E-A89B-C4CDF344FAEF @default.
- Q91455803 P698 Q91455803-29D1C68C-1A1D-40ED-81B1-00510224BF4E @default.
- Q91455803 P921 Q91455803-2A28A059-271E-41D0-A88F-D9E437E99A6D @default.
- Q91455803 P921 Q91455803-A8CB6FC5-18A3-4891-B049-F0D1EADF8AB8 @default.
- Q91455803 P921 Q91455803-C5C68E9E-36BD-41F1-8920-990BACCC8600 @default.
- Q91455803 P932 Q91455803-4EDAD605-0CE3-4219-8BCC-C6482DDF29A1 @default.
- Q91455803 P356 S00280-019-03946-8 @default.
- Q91455803 P698 31768697 @default.
- Q91455803 P1433 Q326137 @default.
- Q91455803 P1476 "Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer" @default.
- Q91455803 P2093 "Carol Cronenberger" @default.
- Q91455803 P2093 "Cheryl S W Li" @default.
- Q91455803 P2093 "Kevin Sweeney" @default.
- Q91455803 P304 "487-499" @default.
- Q91455803 P31 Q13442814 @default.
- Q91455803 P356 "10.1007/S00280-019-03946-8" @default.
- Q91455803 P433 "3" @default.
- Q91455803 P4510 Q4798119 @default.
- Q91455803 P478 "85" @default.
- Q91455803 P577 "2019-11-26T00:00:00Z" @default.
- Q91455803 P698 "31768697" @default.
- Q91455803 P921 Q323936 @default.
- Q91455803 P921 Q3658562 @default.
- Q91455803 P921 Q413299 @default.
- Q91455803 P932 "7036079" @default.